# Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

> **NCT05428449** · PHASE1 · COMPLETED · sponsor: **Suzhou Kintor Pharmaceutical Inc,** · enrollment: 123 (actual)

## Conditions studied

- Androgenetic Alopecia
- Acne Vulgaris

## Interventions

- **DRUG:** GT20029 Gel
- **DRUG:** GT20029 Gel Placebo

## Key facts

- **NCT ID:** NCT05428449
- **Lead sponsor:** Suzhou Kintor Pharmaceutical Inc,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-10
- **Primary completion:** 2022-10-27
- **Final completion:** 2023-04-06
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05428449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05428449, "Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05428449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*